Glutathione is a very popular ingredient in beauty supplements
FDA-approved pharmacotherapy alternatives include several options with established safety profiles: Semaglutide (Wegovy): A GLP-1 receptor agonist producing 12-15% weight loss, with cardiovascular benefits demonstrated in the SELECT trial and FDA-approved indication for reducing cardiovascular risk Liraglutide (Saxenda): A GLP-1 receptor agonist producing 5-8% weight loss [4] Phentermine-topiramate (Qsymia): FDA-approved combination producing 7-10% weight loss with established safety data Naltrexone-bupropion (Contrave): Combination targeting reward pathways and appetite, producing 5-9% weight loss [4] Orlistat (Xenical, Alli): Lipase inhibitor producing 3-5% weight loss with gastrointestinal side effects [4] Setmelanotide (Imcivree): For rare genetic obesity disorders (POMC, PCSK1, LEPR deficiency) [4] Metabolic and bariatric surgery should be considered for patients with BMI 40 kg/m or 35 kg/m with obesity-related comorbidities who have not achieved adequate weight loss with nonsurgical interventions
Menczel Schrire Z, Phillips CL, Chapman JL, Duffy SL, Wong G, DRozario AL, et al
Patients could have also taken their semaglutide inconsistently or stopped taking it, impacting their actual risk
Gssowska-Dobrowolska M, Olech-Kochaczyk G, Culmsee C, Adamczyk A
As part of his preparation, he has focused more on lifting and less on cardiovascular exercise
